Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1106891 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Microbial culture stored at The Herbert Wertheim UF Scripps Institute, Jupiter, Florida, USA - Actinobacteria sp. 012723_197_F08 metagenome
| PRJNA1117955 | ENA
Project description:Synechococcus Metagenomes from Scripps Institute Pier
| PRJNA66351 | ENA
Project description:Huh-7.5.1 cells were treated with 0.2% DMSO, 20 microM NeoB for 24 h. Treatment with 0.2% DMSO for 24h was prepared as non-treated Huh7.5.1 cells. Huh7.5.1 cells were kindly provided by Prof. Francis Chisari at The Scripps Research Institute.
2015-08-31 | GSE63026 | GEO
Project description:Genome sequencing of actinomycetes for natural products discovery
| PRJNA393980 | ENA
Project description:H3K4me1 binding in murine pre-B cells detected by ChIP-seq. For the ChIP-seq, input and immunoprecipitated DNA was given to the TSRI Next Generation Sequencing Core (the Scripps Research Institute, La Jolla, CA, US), where it was prepared for massively parallel sequencing on Illumina HiSeq2000.
2016-10-25 | E-GEOD-79054 | biostudies-arrayexpress
Project description:Over the last 60 years, marine natural products have had major economic and commercial importance. The development of a National Marine Biodiscovery Laboratory in Ireland (NMBLI), located at the Marine Institute (Oranmore), aims to strengthen Ireland’s capacity as research leaders in marine biotechnology and in particularly marine natural products chemistry. The NMBLI houses an Irish marine repository derived from marine macro-organisms collected in Irish coastal waters. The aim of this project is to collect organisms for the marine repository and identify samples of interest for chemical investigation. Other than the development of the laboratory at the marine institute (Oranmore) with the appropriate facilities and procedure to undertake biodiscovery research, the outcomes of this project are to identify bioactive marine natural products from Irish marine life.
2020-02-12 | MTBLS874 | MetaboLights
Project description:The Library of Integrated Cellular Signatures (LINCS) is an NIH program which funds the generation of perturbational profiles across multiple cell and perturbation types, as well as read-outs, at a massive scale. The LINCS Center for Transcriptomics at the Broad Institute uses the L1000 high-throughput gene-expression assay to build a Connectivity Map which seeks to enable the discovery of functional connections between drugs, genes and diseases through analysis of patterns induced by common gene-expression changes. The platform is GPL20573: Broad Institute Human L1000 epsilon http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL20573 For questions or assistance with this dataset, please email the CMap support team at: clue@broadinstitute.org
2015-07-15 | GSE70138 | GEO
Project description:Huh-7.5.1 cells were treated with 0.2% DMSO, 20 microM NeoB for 24 h. Treatment with 0.2% DMSO for 24h was prepared as non-treated Huh7.5.1 cells. Huh7.5.1 cells were kindly provided by Prof. Francis Chisari at The Scripps Research Institute. Total RNA obtained from NeoB-treated and un-treated Huh7.5.1 cells
2015-08-31 | E-GEOD-63026 | biostudies-arrayexpress
Project description:A total of 38 flash-frozen breast cancer tissues were collected from three medical centers in the Netherlands (i.e. National Cancer institute: n=19; Radboud University Medical Center: n=4; Erasmus University Medical Center: n=15). All tissues were analyzed as laser capture microdissected (LCM) and whole samples (whole tissue lysate: WTL). All gathered samples were primary estrogen receptor (ER) tumors, which were subdivided in two patient groups according to outcome to first line (i.e. recurrent disease setting) tamoxifen therapy based on time-to-progression (TTP): patients which manifested progression of disease before (i.e. TTP <=) 6 months were defined as "poor outcome", while patients which manifested progression after (i.e. TTP>) 6 months were defined as "good outcome". All patients did not receive adjuvant hormonal therapy (i.e. tamoxifen or aromatase inhibitors post-surgical resection of primary tumor). The LCM subset derives from PXD000484 (Erasmus Medical Center samples) and PXD000485 (National Cancer Institute and Radboud University Medical Center).
2016-03-31 | PXD002381 | Pride